Physiomics completes Innovate UK oesophageal cancer project

The AIM-traded company said the project was formally signed off by Innovate UK following a final project meeting in February.

It also confirmed that, in line with expectations, it received total funding of £0.13m from Innovate UK over the course of the project, of which around £0.08m would be recognised in its current financial year.

The project, ‘Decision Support System For Stratified Cancer Treatment’, analysed data from more than 400 oesophageal cancer patients to determine patient and disease-specific factors that could help guide treatment to achieve the best outcomes.

It also created a tool for healthcare professionals to visualise that data.

The project was conducted in collaboration with professor Mark Middleton of Oxford University and the Oxford AHSN, with the company intending to publicise the key results and findings of the project through an abstract, poster and other publications over the course of 2018.

Physiomics said the results and learnings from the project had potential applications in both the company's existing business advising research and development-based pharmaceutical and biotech companies, as well as in the emerging field of personalised cancer treatment.

In order to further develop the technology, the company said it was actively seeking additional grants in the space as originally announced in October last year.

“The company believes that the field of personalised or stratified cancer treatment, whether in research and development or in clinical practice, will continue to gain importance in the short to medium term and that the company is well positioned to contribute towards its development,” the board of Physiomics said in its short statement.